April flash PMIs challenge expectations of activity rebound in Q2

This morning the release of the April flash PMIs for the euro area again defied expectations of a rebound and continued to weaken further. The euro area flash composite PMI was reported at 51.3, down from 51.6. Among sectors, confidence receded in the service sector (52.5, from 53.3) but advanced in the manufacturing sector (47.8, from 47.5).

Highlights:

  • With a reading of 51.3, the euro area composite flash PMI for April receded again, thereby surprising on the downside.
  • The deterioration is due to lower service sector sentiment whereas manufacturing sentiment improved, in line with latest signals about strengthening global activity.
  • The details suggest that sentiment deterioration in Southern European economies (Italy, Spain) mainly stands behind the disappointing euro area PMI reading.
  • Today’s PMI data would suggest a meagre Q2 GDP growth rate of just 0.16% qoq, thereby challenging our view of strengthening activity in Q2.

Download the full publication below

APRIL FLASH PMIS CHALLENGE EXPECTATIONS OF ACTIVITY REBOUND IN Q2

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.